"Unchartered territory requires a new way of thinking that isn't one size fits all. As we shift towards novel therapeutic modalities, we are paving the way to better treat complex diseases and modulate previously inaccessible targets," adds Younger. "Drug discovery and the biotech industry are in a very exciting, disruptive period. "It's great to see that our team's focus on the fastest possible turn-around times in the design-make-test-analyse cycle is achieving significant outcomes for our clients."
#Stock icons drug discovery full
"We consider the unique science and needs of each of our partners to create a highly tailored approach that includes everything from custom assays to full program design," says Jeff O'Meara, Vice President Drug Discovery, Dalriada. Their team has become a most trusted partner for Dunad." "Dalriada has consistently invested in the science and focused on meeting our objectives. Graham Simpson, Senior Vice President Drug Discovery, Dunad. "Dalriada has provided the perfect model to support a rapidly growing company like Dunad. To scale up at the pace we have, proactive communication and quick turn-around times from resource deployment to the design-make-test-analyse cycles are critical," says Dr. As part of their Turn-key TM model, Dalriada has been providing integrated drug discovery support for Dunad across medicinal chemistry, biophysics, cell and molecular biology and proteomics. We've had the privilege of supporting Dunad to rapidly scale and further validate their platform technology, and to continue supporting the quick advancement of their pipeline."ĭunad's unique platform offers a target-class agnostic mechanism of action that is clearly differentiated from other targeted protein degradation technologies.
"It takes an agile and innovative team to advance a novel therapeutic modality. Charlie Younger, Chief Operating Officer, Dalriada.
"We are very pleased to see the impact and application of Dunad's technology amplified through the collaboration with Novartis," says Dr. Since its inception Dunad's R&D has been supported by Dalriada, a contract research organization to enable the development of their novel therapeutic modality that uses mono-valent small molecules to induce selective degradation of proteins via direct modification of the target. This leading-edge technology has the potential to deliver next-generation therapeutics with advantages over traditional drugs against a wide range of diseases by unlocking access to disease-causing and often undruggable targets.
#Stock icons drug discovery license
4, 2021 /PRNewswire/ - Dalriada is pleased to congratulate Dunad Therapeutics on its strategic collaboration and license agreement with Novartis potentially worth $1.35 billion, to generate orally bioavailable covalent and protein degrading small molecule drugs. Dalriada has worked with Dunad since its inception to support the development of its novel small molecule protein degradation modality
0 kommentar(er)
